Compare · FLGC vs JNJ
FLGC vs JNJ
Side-by-side comparison of Flora Growth Corp. (FLGC) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLGC and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $567.28B, about 6041.1x FLGC ($93.9M).
- Over the past year, FLGC is down 68.8% and JNJ is up 51.9% - JNJ leads by 120.6 points.
- JNJ has hit the wire 15 times in the past 4 weeks while FLGC has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 3 for FLGC).
- Company
- Flora Growth Corp.
- Johnson & Johnson
- Price
- $8.61-24.24%
- $235.78-2.10%
- Market cap
- $93.9M
- $567.28B
- 1M return
- +17.46%
- +2.16%
- 1Y return
- -68.77%
- +51.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 15
- Recent ratings
- 3
- 25
Flora Growth Corp.
Flora Growth Corp., a cannabis company, cultivates, processes, and supplies cannabis products to pharmacies, medical clinics, and cosmetic companies worldwide. It cultivates, processes, and supplies medicinal-grade cannabis oil, and cannabis oil extracts and related products; manufactures and sells skincare and beauty products, such as gel cleanser, eye cream, moisturizer, and hydrating mask; manufactures dermo cosmetic products; and develops and sells pharmaceutical and over-the-counter products, including dietary supplements, phytotherapeutic and nutraceutical products, supplements, and related products. It also manufactures and sells hemp textiles products focuses on servicing the hospitality, medical, and clothing industries on a B2B basis; designs, produces, and supplies juices, chocolate, and chocolate related products to wholesale distributors, pharmacies, supermarkets, and online distributors; and offers and wellness products. The company's brand includes Mambe, Mind Naturals, Almost Virgin, Flora Lab, and Stardog Loungewear. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest FLGC
- Flora Growth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Flora Growth Corp.
- SEC Form FWP filed by Flora Growth Corp.
- SEC Form 424B3 filed by Flora Growth Corp.
- Flora Growth Corp. Announces Name Change to ZeroStack Corp., Furthering Its Strategy as an AI-Focused Asset Management Company
- SEC Form EFFECT filed by Flora Growth Corp.
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
- SEC Form 3 filed by new insider Zeifman Laurence
- SEC Form S-3 filed by Flora Growth Corp.
- Flora Growth Corp. filed SEC Form 8-K: Leadership Update
Latest JNJ
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
- EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm